Accelerated Vaccination Schedule Against Hepatitis B Virus With Combined Hepatitis A and B Vaccine Among Hemodialysis Patients
NCT ID: NCT03149874
Last Updated: 2023-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
114 participants
INTERVENTIONAL
2014-12-01
2017-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Two Schedules of Hepatitis B Vaccination in Predialysis Chronic Renal Failure Patients
NCT01468051
Research on Optimal Immunization Strategy of Hepatitis B Vaccine in Chronic Kidney Disease Population
NCT03962881
Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients
NCT02963714
Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)
NCT00440297
Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine
NCT01951677
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hepatitis B recombinant DNA vaccine
Each Hepatitis B recombinant DNA vaccine vial contained 20 microgram of vaccine dose. Two vials will be intramuscularly injected one vial in each deltoid muscle on months zero, one, two and six.
Hepatitis B recombinant DNA vaccine
Hepatitis B recombinant DNA vaccine
Combined hepatitis A and B vaccine
Each one-milliliter dose of vaccine contains 720 ELISA units of inactivated hepatitis A virus and 20 mcg of recombinant HBsAg protein. One dose of vaccine also contains 0.45 mg of aluminum. Two vials will be intramuscularly injected one vial in each deltoid muscle on on days zero, seven, and 21.
Combined hepatitis A and B vaccine
Combined hepatitis A and B vaccine given to the patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hepatitis B recombinant DNA vaccine
Hepatitis B recombinant DNA vaccine
Combined hepatitis A and B vaccine
Combined hepatitis A and B vaccine given to the patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hemodialysis patient
* All patients had undetectable hepatitis B virus surface antigen and antibody
Exclusion Criteria
* patient received a previous course of hepatitis B virus vaccine
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
New Jeddah Clinic Hospital
INDUSTRY
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mahmoud Hamada imam
MD. - Lecturer at Internal Medicine Department- Faculty of Medicine
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BN-0517
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.